NASDAQ:IDIX - Idenix Pharmaceuticals Stock Price, Price Target & More

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Idenix Pharmaceuticals (NASDAQ:IDIX)

Idenix Pharmaceuticals logoIdenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.

Receive IDIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

How to Become a New Pot Stock Millionaire

Idenix Pharmaceuticals (NASDAQ:IDIX) Frequently Asked Questions

What is Idenix Pharmaceuticals' stock symbol?

Idenix Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDIX."

Has Idenix Pharmaceuticals been receiving favorable news coverage?

News stories about IDIX stock have been trending positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Idenix Pharmaceuticals earned a media sentiment score of 0.35 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 48.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Idenix Pharmaceuticals?

Shares of IDIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Idenix Pharmaceuticals?

Idenix Pharmaceuticals' mailing address is 320 Bent St, CAMBRIDGE, MA 02141-2025, United States. The biopharmaceutical company can be reached via phone at +1-617-9959800.

MarketBeat Community Rating for Idenix Pharmaceuticals (IDIX)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  280
MarketBeat's community ratings are surveys of what our community members think about Idenix Pharmaceuticals and other stocks. Vote "Outperform" if you believe IDIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDIX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Idenix Pharmaceuticals (NASDAQ:IDIX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/25/2016 forward)


Idenix Pharmaceuticals (NASDAQ:IDIX) Earnings History and Estimates Chart

Earnings by Quarter for Idenix Pharmaceuticals (NASDAQ:IDIX)

Idenix Pharmaceuticals (NASDAQ IDIX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2014Q214($0.22)($0.43)($26.07) millionViewN/AView Earnings Details
5/1/2014Q114($0.19)($0.24)$0.22 million($3.01) millionViewN/AView Earnings Details
2/27/2014Q413($0.22)($0.21)$0.15 million$0.50 millionViewN/AView Earnings Details
10/30/2013Q3 2013($0.21)($0.25)$2.13 million$0.02 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.23)($0.22)$0.30 million$0.11 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.18)($0.23)$0.33 million$0.85 millionViewN/AView Earnings Details
2/25/2013Q412($0.17)($0.17)$0.74 million$0.3270 millionViewN/AView Earnings Details
11/1/2012Q312($0.17)$0.03$2.60 million$32.30 millionViewN/AView Earnings Details
8/8/2012Q2 2012($0.21)($0.23)ViewN/AView Earnings Details
5/2/2012Q1 2012$0.18$0.10ViewN/AView Earnings Details
2/23/2012Q4 2011($0.15)($0.18)ViewN/AView Earnings Details
11/2/2011Q3 2011($0.16)($0.12)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.13)($0.15)ViewN/AView Earnings Details
4/27/2011Q1 2011($0.14)($0.11)ViewN/AView Earnings Details
2/28/2011Q4 2010($0.18)($0.22)ViewN/AView Earnings Details
10/29/2010Q3 2010($0.22)($0.18)ViewN/AView Earnings Details
7/26/2010Q2 2010($0.14)($0.23)ViewN/AView Earnings Details
5/3/2010Q1 2010($0.20)($0.24)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.19)($0.19)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.23)($0.18)ViewN/AView Earnings Details
7/20/2009Q2 2009($0.25)($0.28)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.12)($0.23)ViewN/AView Earnings Details
2/17/2009Q4 2008($0.22)($0.25)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.33)($0.30)ViewN/AView Earnings Details
7/29/2008Q2 2008($0.35)($0.34)ViewN/AView Earnings Details
4/29/2008Q1 2008($0.25)($0.36)ViewN/AView Earnings Details
3/6/2008Q4 2007($0.45)($0.28)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Idenix Pharmaceuticals (NASDAQ:IDIX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Idenix Pharmaceuticals (NASDAQ IDIX) Insider Trading and Institutional Ownership History

Insider Trading History for Idenix Pharmaceuticals (NASDAQ:IDIX)

Idenix Pharmaceuticals (NASDAQ IDIX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2014Baupost Group Llc/Mamajor shareholderBuy16,420,241$6.50$106,731,566.50View SEC Filing  
(Data available from 1/1/2013 forward)


Idenix Pharmaceuticals (NASDAQ IDIX) News Headlines

Belgian scientists claim Delaware wrongly seized, sold stockBelgian scientists claim Delaware wrongly seized, sold stock - October 13 at 7:33 PM
Head-To-Head Analysis: Idenix Pharmaceuticals (IDIX) versus Grifols, (GRFS)Head-To-Head Analysis: Idenix Pharmaceuticals (IDIX) versus Grifols, (GRFS) - September 7 at 2:28 AM
Heres where Mercks new Cambridge research facility will be locatedHere's where Merck's new Cambridge research facility will be located - July 13 at 4:30 PM
3 Important Questions We Want Answered When Merck Reports Its Q2 Results3 Important Questions We Want Answered When Merck Reports Its Q2 Results - July 27 at 9:02 AM
Activists want imminent retirement of Ariad CEOActivists want 'imminent retirement' of Ariad CEO - February 20 at 11:24 AM

SEC Filings

Idenix Pharmaceuticals (NASDAQ:IDIX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Idenix Pharmaceuticals (NASDAQ:IDIX) Income Statement, Balance Sheet and Cash Flow Statement


Idenix Pharmaceuticals (NASDAQ IDIX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.